Medicenna Therapeutics
Dr. Martin Bexon, MD, has more than 15 years of experience in early and late stage clinical development including medical affairs in various therapeutic areas, particularly in oncology and hematology. He has recently worked as a strategic adviser, study medical expert, and medical monitor in a number of oncology programs (U.S. and E.U.), in both solid tumors and hematological malignancies. While at CSL Behring (Bern, Switzerland) he led multiple global clinical studies across a range of indications including orphan diseases. As Global Medical Director, Dr. Bexon also led their medical affairs function for immunoglobulin products, generating more than 50% of the company’s revenues. At Hoffman-La Roche (U.K. and Switzerland) he designed and implemented multiple global clinical trials enrolling more than 10,000 subjects to support product commercialization. He has also led teams to file numerous regulatory submissions on both sides of the Atlantic and Japan. Prior to joining pharma, he practiced in the clinic as a pediatrician. He obtained his MBBS (MD equivalent) from the University of Newcastle upon Tyne, U.K.
This person is not in any offices
Medicenna Therapeutics
1 followers
Medicenna Therapeutics is a clinical-stage immunotherapy company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines (ECs). Their mission is to become the leader in the development and commercialization of targeted ECs and Superkines for the treatment of a broad range of cancers and immune-mediated diseases.